Form 4: Twist Bioscience CEO Emily Leproust Sells Shares to Cover Tax Obligations

Emily Leproust, CEO of Twist Bioscience, sold 492 shares of common stock on April 2, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 2, 2025, Emily M. Leproust, CEO of Twist Bioscience, sold 492 shares of Twist Bioscience Corp (TWST) common stock at a price of $38.733 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Leproust continues to hold 660,474 shares of Twist Bioscience common stock directly.
• Leproust also holds employee stock options with various exercise prices and expiration dates.
• These options include 150,879 options with an exercise price of $8.82 expiring on September 28, 2027, 266,539 options with an exercise price of $26.66 expiring on November 18, 2028, and 131,290 options with an exercise price of $23.33 expiring on October 23, 2029.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a routine transaction to cover tax obligations and doesn't necessarily indicate a change in the executive's confidence in the company.

Industry Context

This is a routine Form 4 filing, indicating insider activity related to stock compensation. It's common for executives to sell shares to cover tax obligations when stock options or restricted stock units vest.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, Emily Leproust, Twist Bioscience, TWST, tax withholding